{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:26:28Z","timestamp":1789453588427,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Helsinki including Helsinki University Central Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Many drugs are associated with the risk of QT prolongation and torsades de pointes (TdP), and different risk assessment tools (RATs) are developed to help clinicians to manage related risk. The aim of this systematic review was to summarize the evidence of different RATs for QT prolonging pharmacotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic review was conducted using PubMed and Scopus databases. Studies concerning risk assessment tools for QT prolonging pharmacotherapy, including older adults, were included. Screening and selection of the studies, data extraction, and risk of bias assessment were undertaken.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 21 studies were included, involving different risk assessment tools. Most commonly used tools were risk scores (<jats:italic>n<\/jats:italic>\u2009=\u20099), computerized physician order entry systems (<jats:italic>n<\/jats:italic>\u2009=\u20093), and clinical decision support systems (<jats:italic>n<\/jats:italic>\u2009=\u20096). The tools were developed mainly for physicians and pharmacists. Risk scores included a high number of risk factors, both pharmacological and non-pharmacological, for QT prolongation and TdP. The inclusion of patients\u2019 risk factors in computerized physician order entry and clinical decision support systems varied.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Most of the risk assessment tools for QT prolonging pharmacotherapy give a comprehensive overview of patient-specific risks of QT prolongation and TdP and reduce modifiable risk factors and actual events. The risk assessment tools could be better adapted to different health information systems to help in clinical decision-making. Further studies on clinical validation of risk assessment tools with randomized controlled trials are needed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-022-03285-3","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T04:16:27Z","timestamp":1644812187000},"page":"765-779","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Risk assessment tools for QT prolonging pharmacotherapy in older adults: a systematic review"],"prefix":"10.1007","volume":"78","author":[{"given":"Simone","family":"Skullbacka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6077-5671","authenticated-orcid":false,"given":"Marja","family":"Airaksinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4033-1539","authenticated-orcid":false,"given":"Juha","family":"Puustinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8357-2714","authenticated-orcid":false,"given":"Terhi","family":"Toivo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"3285_CR1","unstructured":"Woosley RL, Heise CW, Romero KA (2018) QTdrugs List, January 2018, AZCERT, Inc. 1822 Innovation Park Dr., Oro Valley, AZ 85755. Available at: www.crediblemeds.org Accessed January 24, 2018"},{"issue":"3","key":"3285_CR2","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/bcp.12726","volume":"81","author":"SHL Thomas","year":"2016","unstructured":"Thomas SHL, Behr ER (2016) Pharmacological treatment of acquired QT prolongation and torsades de pointes. Br J Clin Pharmacol 81(3):420\u2013427","journal-title":"Br J Clin Pharmacol"},{"key":"3285_CR3","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.jacc.2015.12.063","volume":"67","author":"PJ Schwartz","year":"2016","unstructured":"Schwartz PJ, Woosley RL (2016) Predicting the unpredictable. Drug-induced QT prolongation and torsades de pointes. J Am Coll Cardiol 67:1639\u20131650","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"3285_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11096-016-0414-2","volume":"39","author":"E Vandael","year":"2017","unstructured":"Vandael E, Vandenberk B, Vandenberghe J et al (2017) Risk factors for QTc-prolongation: systematic review of the evidence. Int J Clin Pharm 39(1):16\u201325","journal-title":"Int J Clin Pharm"},{"issue":"7","key":"3285_CR5","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.amjcard.2015.01.016","volume":"115","author":"Z Laksman","year":"2015","unstructured":"Laksman Z, Momciu B, Seong YW et al (2015) A detailed description and assessment of outcomes of patients with hospital recorded QTc prolongation. Am J Cardiol 115(7):907\u2013911","journal-title":"Am J Cardiol"},{"issue":"8","key":"3285_CR6","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.109.192704","volume":"121","author":"BJ Drew","year":"2010","unstructured":"Drew BJ, Ackerman MJ, Funk M et al (2010) Prevention of Torsade de Pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 121(8):1047\u20131060","journal-title":"Circulation"},{"key":"3285_CR7","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/bcp.12969","volume":"82","author":"PA Moreno-Guti\u00e9rrez","year":"2016","unstructured":"Moreno-Guti\u00e9rrez PA, Gaviria-Mendoza A, Montoya Ca\u00f1\u00f3n M et al (2016) High prevalence of risk factors in elderly patients using drugs associated with acquired torsades de pointes chronically in Colombia. Br J Clin Pharmacol 82:504\u2013511","journal-title":"Br J Clin Pharmacol"},{"key":"3285_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0002-9343(02)01455-9","volume":"114","author":"LH Curtis","year":"2003","unstructured":"Curtis LH, \u00d8stbye T, Sendersky V et al (2003) Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 114:135\u2013141","journal-title":"Am J Med"},{"issue":"1","key":"3285_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/pds.3455","volume":"23","author":"K Tay","year":"2014","unstructured":"Tay K, Ewald MB, Bourgeois FT (2014) Use of QT-prolonging medications in US emergency departments, 1995\u20132009. Pharmacoepidemiol Drug Saf 23(1):9\u201317","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3285_CR10","doi-asserted-by":"crossref","unstructured":"Sch\u00e4chtele S, T\u00fcmena T, Ga\u00dfmann KG et al (2016) Co-prescription of QT-interval prolonging drugs: an analysis in a large cohort of geriatric patients. PLoS One 11(5):e0155649.","DOI":"10.1371\/journal.pone.0155649"},{"issue":"10","key":"3285_CR11","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMra032426","volume":"350","author":"DM Roden","year":"2004","unstructured":"Roden DM (2004) Drug-induced prolongation of the QT interval. N Engl J Med 350(10):1013\u20131022","journal-title":"N Engl J Med"},{"issue":"4","key":"3285_CR12","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1161\/CIRCOUTCOMES.113.000152","volume":"6","author":"JE Tisdale","year":"2013","unstructured":"Tisdale JE, Jaynes HA, Kingery JR et al (2013) Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 6(4):479\u2013487","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"4","key":"3285_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1046\/j.1540-8167.2001.00411.x","volume":"12","author":"M Malik","year":"2001","unstructured":"Malik M (2001) Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 12(4):411\u2013420","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"2","key":"3285_CR14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s11096-017-0446-2","volume":"39","author":"E Vandael","year":"2017","unstructured":"Vandael E, Vandenberk B, Vandenberghe J et al (2017) Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm 39(2):424\u2013432","journal-title":"Int J Clin Pharm"},{"key":"3285_CR15","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097","DOI":"10.1371\/journal.pmed.1000097"},{"key":"3285_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"3285_CR17","unstructured":"World Health Organization (2017) WHO: proposed working definition of an older person in Africa for the MDS Project. (online) Available at: www.who.int. Accessed October 8, 2017"},{"issue":"7650","key":"3285_CR18","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926","journal-title":"BMJ"},{"key":"3285_CR19","doi-asserted-by":"crossref","unstructured":"B\u00f6ttiger Y, Laine K, Korhonen T et al (2017) Development and pilot testing of PHARAO\u2014a decision support system for pharmacological risk assessment in the elderly. Eur J Clin Pharmacol 1\u20137","DOI":"10.1007\/s00228-017-2391-3"},{"issue":"4","key":"3285_CR20","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00134-010-1778-8","volume":"36","author":"T Bertsche","year":"2010","unstructured":"Bertsche T, Pfaff J, Schiller P et al (2010) Prevention of adverse drug reactions in intensive care patients by personal intervention based on an electronic clinical decision support system. Intensive Care Med 36(4):665\u2013672","journal-title":"Intensive Care Med"},{"issue":"4","key":"3285_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.mayocp.2013.01.013","volume":"88","author":"KH Haugaa","year":"2013","unstructured":"Haugaa KH, Bos JM, Tarrell RF (2013) Institution-wide QT alert system identifies patients with a high risk of mortality. Mayo Clin Proc 88(4):315\u2013325","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"3285_CR22","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/j.amjcard.2015.08.027","volume":"116","author":"DD Joyce","year":"2015","unstructured":"Joyce DD, Bos JM, Haugaa KH et al (2015) Frequency and cause of transient QT prolongation after surgery. Am J Cardiol 116(10):1605\u20131609","journal-title":"Am J Cardiol"},{"issue":"2","key":"3285_CR23","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s11096-015-0242-9","volume":"38","author":"E Vandael","year":"2016","unstructured":"Vandael E, Vandenberk B, Vandenberghe J et al (2016) Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium. Int J Clin Pharm 38(2):310\u2013320","journal-title":"Int J Clin Pharm"},{"key":"3285_CR24","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.ijcard.2017.05.072","volume":"243","author":"E Vandael","year":"2017","unstructured":"Vandael E, Vandenberk B, Vandenberghe J et al (2017) Incidence of Torsade de Pointes in a tertiary hospital population. Int J Cardiol 243:511\u2013515","journal-title":"Int J Cardiol"},{"key":"3285_CR25","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3390\/jcm7120533","volume":"7","author":"VH Buss","year":"2018","unstructured":"Buss VH, Lee K, Naunton M et al (2018) Identification of patients at-risk of QT interval prolongation during medication reviews: a missed opportunity? J Clin Med 7:533","journal-title":"J Clin Med"},{"issue":"5","key":"3285_CR26","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1007\/s11096-018-0692-y","volume":"40","author":"AN Bindraban","year":"2018","unstructured":"Bindraban AN, Rolvink J, Berger FA et al (2018) Development of a risk model for predicting QTc interval prolongation in patients using QTc-prolonging drugs. Int J Clin Pharm 40(5):1372\u20131379. https:\/\/doi.org\/10.1007\/s11096-018-0692-y","journal-title":"Int J Clin Pharm"},{"issue":"12","key":"3285_CR27","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1111\/bcp.13740","volume":"84","author":"E Vandael","year":"2018","unstructured":"Vandael E, Vandenberk B, Vandenberghe J et al (2018) A smart algorithm for the prevention and risk management of QTc prolongation based on the optimized RISQ-PATH model. Br J Clin Pharmacol 84(12):2824\u20132835. https:\/\/doi.org\/10.1111\/bcp.13740","journal-title":"Br J Clin Pharmacol"},{"key":"3285_CR28","first-page":"353","volume":"7","author":"H Bazett","year":"1920","unstructured":"Bazett H (1920) An analysis of the time relationship of electrocardiograms. Heart 7:353\u2013370","journal-title":"Heart"},{"key":"3285_CR29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.0954-6820.1920.tb18267.x","volume":"53","author":"LS Fridericia","year":"1920","unstructured":"Fridericia LS (1920) Die Systolendauer im elektrokardiogramm bei normalen menschen und bei herzkranken. Acta Med Scand 53:489","journal-title":"Acta Med Scand"},{"key":"3285_CR30","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.amjcard.2003.12.055","volume":"93","author":"PM Rautaharju","year":"2004","unstructured":"Rautaharju PM, Zhang ZM, Prineas R, Heiss G (2004) Assessment of prolonged QT and JT intervals in ventricular conduction defects. Am J Cardiol 93:1017\u20131021","journal-title":"Am J Cardiol"},{"issue":"9","key":"3285_CR31","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s00228-009-0654-3","volume":"65","author":"H van der Sijs","year":"2009","unstructured":"van der Sijs H, Kowlesar R, Aarts J et al (2009) Unintended consequences of reducing QT-alert overload in a computerized physician order entry system. Eur J Clin Pharmacol 65(9):919\u2013925","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"3285_CR32","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/BF03261969","volume":"35","author":"A Muzyk","year":"2012","unstructured":"Muzyk A, Rivelli S, Jiang W et al (2012) A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization. Drug Saf 35(9):725\u2013731","journal-title":"Drug Saf"},{"key":"3285_CR33","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1136\/amiajnl-2014-002896","volume":"22","author":"A Sorita","year":"2015","unstructured":"Sorita A, Bos JM, Morlan BW et al (2015) Impact of clinical decision support preventing the use of QT-prolonging medications for patients at risk for torsade de pointes. J Am Med Inform Assoc 22:e21\u2013e27","journal-title":"J Am Med Inform Assoc"},{"issue":"1","key":"3285_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s002280050714","volume":"56","author":"F De Ponti","year":"2000","unstructured":"De Ponti F, Poluzzi E, Montanaro N (2000) QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 56(1):1\u201318","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"3285_CR35","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s002280100290","volume":"57","author":"F De Ponti","year":"2001","unstructured":"De Ponti F, Poluzzi E, Montanaro N (2001) Organising evidence on QT prolongation and occurrence of torsades de pointes with non-antiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol 57(3):185\u2013209","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"3285_CR36","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1161\/CIRCOUTCOMES.113.000651","volume":"7","author":"JE Tisdale","year":"2014","unstructured":"Tisdale JE, Jaynes HA, Kingery JR et al (2014) Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 7(3):381\u2013390","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"3285_CR37","doi-asserted-by":"crossref","unstructured":"Berger FA, van der Sijs H, Becker ML et al (2020) Development and validation of a tool to assess the risk of QT drug-drug interactions in clinical practice. BMC Med Inform Decis Mak 20: 171","DOI":"10.1186\/s12911-020-01181-3"},{"key":"3285_CR38","doi-asserted-by":"publisher","unstructured":"Chernoby K, Lucey MF, Hartner CL, Dehoorne M, Edwin SB (2020) Impact of a clinical decision support tool targeting QT-prolonging medications. Am J Health Syst Pharm 77(Supplement_4):S111-S117. https:\/\/doi.org\/10.1093\/ajhp\/zxaa269","DOI":"10.1093\/ajhp\/zxaa269"},{"key":"3285_CR39","doi-asserted-by":"publisher","first-page":"204209862199609","DOI":"10.1177\/2042098621996098","volume":"12","author":"FA Berger","year":"2021","unstructured":"Berger FA, van der Sijs H, van Gelder T, van den Bemt PMLA (2021) The use of a clinical decision support tool to assess the risk of QT drug-drug interactions in community pharmacies. Ther Adv Drug Saf 12:2042098621996098","journal-title":"Ther Adv Drug Saf"},{"issue":"10","key":"3285_CR40","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/qjmed\/hcm072","volume":"100","author":"A Chan","year":"2007","unstructured":"Chan A, Isbister GK, Kirkpatrick CMJ et al (2007) Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. QJM 100(10):609\u2013615","journal-title":"QJM"},{"issue":"1","key":"3285_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/jpet.104.073288","volume":"312","author":"AA Fossa","year":"2005","unstructured":"Fossa AA, Wisialowski T, Magnano A et al (2005) Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition. J Pharmacol Exp Ther 312(1):1\u201311","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"3285_CR42","first-page":"277","volume":"42","author":"GK Isbister","year":"2004","unstructured":"Isbister GK, Bowe SJ, Dawson A et al (2004) Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. Clin Toxicol 42(3):277\u2013285","journal-title":"Clin Toxicol"},{"issue":"10","key":"3285_CR43","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/acem.12752","volume":"22","author":"I Berling","year":"2015","unstructured":"Berling I, Isbister GK (2015) The half RR rule: a poor rule of thumb and not a risk assessment tool for QT interval prolongation. Acad Emerg Med 22(10):1139\u20131144","journal-title":"Acad Emerg Med"},{"issue":"5","key":"3285_CR44","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10557-015-6619-0","volume":"29","author":"A Sugrue","year":"2015","unstructured":"Sugrue A, Kremen V, Qiang B et al (2015) Electrocardiographic predictors of torsadogenic risk during dofetilide or sotalol initiation: utility of a novel T wave analysis program. Cardiovasc Drugs Ther 29(5):433\u2013441","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"3285_CR45","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1197\/jamia.M1809","volume":"13","author":"H van der Sijs","year":"2006","unstructured":"van der Sijs H, Aarts J, Vulto A et al (2006) Overriding of drug safety alerts in computerized physician order entry. J Am Med Inform Assoc 13(2):138\u2013147","journal-title":"J Am Med Inform Assoc"},{"key":"3285_CR46","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jelectrocard.2004.08.030","volume":"37","author":"S Luo","year":"2004","unstructured":"Luo S, Michler K, Johnston P et al (2004) A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs. J Electrocardiol 37:81\u201390","journal-title":"J Electrocardiol"},{"key":"3285_CR47","doi-asserted-by":"crossref","unstructured":"Vandenberk B, Vandael E, Robyns T et al (2016) Which QT correction formulae to use for QT monitoring? J Am Heart Assoc 5(6):e003264","DOI":"10.1161\/JAHA.116.003264"},{"key":"3285_CR48","doi-asserted-by":"crossref","unstructured":"Toivo T, Dimitrow M, Puustinen J et al (2018) Coordinating resources for prospective medication risk management of older home care clients in primary care: procedure development and RCT study design for demonstrating its effectiveness. BMC Geriatr 18(74):1\u201310","DOI":"10.1186\/s12877-018-0737-z"},{"key":"3285_CR49","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/j.1525-1497.2005.0101.x","volume":"20","author":"SM Al-Khatib","year":"2005","unstructured":"Al-Khatib SM, Allen LaPointe NM, Kramer JM et al (2005) A survey of health care practitioners\u2019 knowledge of the QT interval. J Gen Intern Med 20:392\u2013396","journal-title":"J Gen Intern Med"},{"issue":"1","key":"3285_CR50","first-page":"119","volume":"18","author":"E Vandael","year":"2018","unstructured":"Vandael E, Verstuyft E, Leirs C et al (2018) An e-learning programme about the risk and management of QTc-prolongation in community pharmacies significantly improves pharmacists\u2019 (longterm) knowledge. Pharm Educ 18(1):119\u2013131","journal-title":"Pharm Educ"},{"key":"3285_CR51","unstructured":"Sch\u00fcnemann H, Jan Bro\u017cek J, Guyatt G et al (2018) GRADE handbook, 2013 (online). Available at: http:\/\/gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html. Accessed May 09, 2018."},{"issue":"Suppl K","key":"3285_CR52","doi-asserted-by":"publisher","first-page":"K70","DOI":"10.1016\/S1520-765X(01)90009-4","volume":"3","author":"B Darp\u00f6","year":"2001","unstructured":"Darp\u00f6 B (2001) Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J Suppl 3(Suppl K):K70\u2013K80","journal-title":"Eur Heart J Suppl"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03285-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03285-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03285-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T08:07:56Z","timestamp":1649750876000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03285-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["3285"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03285-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]},"assertion":[{"value":"2 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}